Gilead names remdesivir price
The treatment will cost $3,120 for a five-day treatment course for a patient with private insurance in the U.S.
News
Point of care and the pandemic
The inside story of how one of healthcare marketing’s most important channels navigated COVID-19 – and may have emerged stronger and smarter.
Five things for pharma marketers to know: Monday, June 29, 2020
Justice Department asks Supreme Court to overturn ACA; States reverse reopening as virus cases climb; Submit creative to MM&M’s #CreateHealthEquity initiative.
Pharma brands tweak media mix to align with their stance on racism
As drug makers mull whether to join a July ad boycott against Facebook, will #BLM prove a tipping point for health brands’ new social activism?
Five things for pharma marketers to know: Friday, June 26, 2020
CDC changes populations at risk for severe COVID-19 illness; Texas pauses reopening as cases spike; CDC considers TikTok to educate young people about virus.
Watch: Klick Health unites from afar to perform “I Can See Clearly Now”
20 staffers – singers, organists, oboists and more – contributed to the performance
The Escalator: Havas Lynx Group appoints co-creative chiefs
Plus people moves at HyperPointe, Conran Design Group and Merge.
Publicis chiefs insist on celebrating awards in Cannes
Journey of Arthur Sadoun and Maurice Lévy to Cannes features in film to promote Cannes-Do Awards.
Five things for pharma marketers to know: Thursday, June 25, 2020
Judge rules hospitals, insurers must disclose some pricing; Remdesivir could be priced at $5,080; Bayer settles Roundup lawsuits.
Publicis Health revamps internship program into virtual summer academy in light of pandemic
The virtual academy allowed Publicis Health to bring in more students from different parts of the country and world.
Want to read more?
Please login or register first to view this content.
